206 related articles for article (PubMed ID: 15335314)
1. Allergy vaccines--new approaches to an old concept.
Wheeler AW; Woroniecki SR
Expert Opin Biol Ther; 2004 Sep; 4(9):1473-81. PubMed ID: 15335314
[TBL] [Abstract][Full Text] [Related]
2. Allergoid-specific T-cell reaction as a measure of the immunological response to specific immunotherapy (SIT) with a Th1-adjuvanted allergy vaccine.
von Baehr V; Hermes A; von Baehr R; Scherf HP; Volk HD; Fischer von Weikersthal-Drachenberg KJ; Woroniecki S
J Investig Allergol Clin Immunol; 2005; 15(4):234-41. PubMed ID: 16433203
[TBL] [Abstract][Full Text] [Related]
3. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
Wheeler AW; Marshall JS; Ulrich JT
Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
[TBL] [Abstract][Full Text] [Related]
4. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study.
Pfaar O; Barth C; Jaschke C; Hörmann K; Klimek L
Int Arch Allergy Immunol; 2011; 154(4):336-44. PubMed ID: 20975285
[TBL] [Abstract][Full Text] [Related]
5. Clinical use of adjuvants in allergen-immunotherapy.
Klimek L; Schmidt-Weber CB; Kramer MF; Skinner MA; Heath MD
Expert Rev Clin Immunol; 2017 Jun; 13(6):599-610. PubMed ID: 28162007
[TBL] [Abstract][Full Text] [Related]
6. A novel adjuvant complex, tyrosine-MPL, for prophylactic and therapeutic vaccines.
Wheeler A
Vaccine; 2006 Apr; 24 Suppl 2():S2-40-1. PubMed ID: 16823919
[TBL] [Abstract][Full Text] [Related]
7. Standardisation of glutaraldehyde-modified tyrosine-adsorbed tree pollen vaccines containing the Th1-inducing adjuvant, monophosphoryl lipid A (MPL).
Hopkins M; Lees BG; Richardson DG; Woroniecki SR; Wheeler AW
Allergol Immunopathol (Madr); 2001; 29(6):245-54. PubMed ID: 11834183
[TBL] [Abstract][Full Text] [Related]
8. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro).
McCormack PL; Wagstaff AJ
Drugs; 2006; 66(7):931-8. PubMed ID: 16740007
[TBL] [Abstract][Full Text] [Related]
9. Long-term effect of monophosphoryl lipid A adjuvanted specific immunotherapy in patients with grass pollen allergy.
Zielen S; Gabrielpillai J; Herrmann E; Schulze J; Schubert R; Rosewich M
Immunotherapy; 2018 Jun; 10(7):529-536. PubMed ID: 29562801
[TBL] [Abstract][Full Text] [Related]
10. Adjuvants for allergen immunotherapy: experimental results and clinical perspectives.
Francis JN; Durham SR
Curr Opin Allergy Clin Immunol; 2004 Dec; 4(6):543-8. PubMed ID: 15640697
[TBL] [Abstract][Full Text] [Related]
11. Specific immunotherapy.
Larché M
Br Med Bull; 2000; 56(4):1019-36. PubMed ID: 11359635
[TBL] [Abstract][Full Text] [Related]
12. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis.
Rosewich M; Lee D; Zielen S
Hum Vaccin Immunother; 2013 Jul; 9(7):1523-31. PubMed ID: 23584250
[TBL] [Abstract][Full Text] [Related]
13. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro): viewpoints.
Jutek M; Bachert C
Drugs; 2006; 66(7):939-40. PubMed ID: 16740008
[No Abstract] [Full Text] [Related]
14. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy.
Rask C; Lund L; Lund G; Heydenreich B; Wurtzen P; Bellinghausen I; Saloga J; Lund K
Clin Exp Allergy; 2012 Sep; 42(9):1356-68. PubMed ID: 22925322
[TBL] [Abstract][Full Text] [Related]
15. The Impact on Allergy-Related Cells of a Birch Pollen Allergoid, with and without Monophosphoryl Lipid A, in Comparison with the Native Equivalent.
Worm M; Ernst D; Kraller M; Babina M
Int Arch Allergy Immunol; 2017; 172(1):20-26. PubMed ID: 28219062
[TBL] [Abstract][Full Text] [Related]
16. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections.
Drachenberg KJ; Wheeler AW; Stuebner P; Horak F
Allergy; 2001 Jun; 56(6):498-505. PubMed ID: 11421893
[TBL] [Abstract][Full Text] [Related]
17. The future of sublingual immunotherapy.
Marcucci F; Duse M; Frati F; Incorvaia C; Marseglia GL; La Rosa M
Int J Immunopathol Pharmacol; 2009; 22(4 Suppl):31-3. PubMed ID: 19944008
[TBL] [Abstract][Full Text] [Related]
18. New strategies for allergen immunotherapy.
Carnés J; Robinson DS
Recent Pat Inflamm Allergy Drug Discov; 2008 Jun; 2(2):92-101. PubMed ID: 19075996
[TBL] [Abstract][Full Text] [Related]
19. Highlights of Novel Vaccination Strategies in Allergen Immunotherapy.
Komlósi ZI; Kovács N; Sokolowska M; van de Veen W; Akdis M; Akdis CA
Immunol Allergy Clin North Am; 2020 Feb; 40(1):15-24. PubMed ID: 31761116
[TBL] [Abstract][Full Text] [Related]
20. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy.
Baldrick P; Richardson D; Wheeler AW
Vaccine; 2001 Dec; 20(5-6):737-43. PubMed ID: 11738737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
